S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
S&P 500   4,571.95 (-1.79%)
DOW   34,487.81 (-1.84%)
QQQ   393.19 (-1.63%)
AAPL   163.65 (+2.13%)
MSFT   330.27 (-1.89%)
FB   326.49 (-3.41%)
GOOGL   2,853.86 (-1.95%)
AMZN   3,503.45 (-1.63%)
TSLA   1,135.00 (-0.18%)
NVDA   322.06 (-3.51%)
BABA   126.80 (-3.65%)
NIO   38.97 (-3.68%)
CGC   10.37 (-6.24%)
AMD   156.68 (-3.23%)
GE   94.83 (-3.63%)
MU   84.61 (-1.78%)
T   22.62 (-5.32%)
F   19.21 (-2.34%)
DIS   143.51 (-2.91%)
ACB   6.18 (-4.04%)
AMC   33.90 (-7.98%)
PFE   53.86 (+2.79%)
BA   194.98 (-1.77%)
NASDAQ:RANI

Rani Therapeutics Stock Forecast, Price & News

$29.31
-0.28 (-0.95%)
(As of 11/30/2021 12:43 PM ET)
Add
Compare
Today's Range
$28.91
$30.00
50-Day Range
$16.09
$35.00
52-Week Range
$9.24
$36.27
Volume
247 shs
Average Volume
224,381 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive RANI News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Rani Therapeutics logo

About Rani Therapeutics

Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RANI
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.44 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/21/2022

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

1150th out of 1,390 stocks

Pharmaceutical Preparations Industry

550th out of 669 stocks

Analyst Opinion: 1.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Rani Therapeutics (NASDAQ:RANI) Frequently Asked Questions

Is Rani Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rani Therapeutics stock.
View analyst ratings for Rani Therapeutics
or view top-rated stocks.

When is Rani Therapeutics' next earnings date?

Rani Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Rani Therapeutics
.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings Inc (NASDAQ:RANI) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02.
View Rani Therapeutics' earnings history
.

What price target have analysts set for RANI?

5 equities research analysts have issued twelve-month target prices for Rani Therapeutics' shares. Their forecasts range from $23.00 to $24.00. On average, they anticipate Rani Therapeutics' share price to reach $23.50 in the next year. This suggests that the stock has a possible downside of 19.8%.
View analysts' price targets for Rani Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Rani Therapeutics IPO?

(RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

What is Rani Therapeutics' stock symbol?

Rani Therapeutics trades on the NASDAQ under the ticker symbol "RANI."

When does the company's lock-up period expire?

Rani Therapeutics' lock-up period expires on Wednesday, January 26th. Rani Therapeutics had issued 6,666,667 shares in its initial public offering on July 30th. The total size of the offering was $73,333,337 based on an initial share price of $11.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are Rani Therapeutics' major shareholders?

Rani Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Caas Capital Management LP (0.15%), Goldman Sachs Group Inc. (0.12%), Squarepoint Ops LLC (0.10%), Millennium Management LLC (0.06%), Geode Capital Management LLC (0.04%) and UBS Group AG (0.01%).

Which institutional investors are buying Rani Therapeutics stock?

RANI stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Goldman Sachs Group Inc., Squarepoint Ops LLC, Millennium Management LLC, Geode Capital Management LLC, and UBS Group AG.

How do I buy shares of Rani Therapeutics?

Shares of RANI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rani Therapeutics' stock price today?

One share of RANI stock can currently be purchased for approximately $29.31.

How much money does Rani Therapeutics make?

Rani Therapeutics has a market capitalization of $1.44 billion.

How many employees does Rani Therapeutics have?

Rani Therapeutics employs 2,021 workers across the globe.

What is Rani Therapeutics' official website?

The official website for Rani Therapeutics is www.ranitherapeutics.com.

How can I contact Rani Therapeutics?

The company can be reached via phone at 408-457-3700 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.